89bio to participate in the h.c. wainwright 6th annual nash investor conference

San francisco, oct. 13, 2022 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that company's management will participate in a fireside chat and one-on-one investor meetings at the h.c. wainwright 6th annual nash investor conference on monday, october 17, 2022 at 11:30 am et.
ETNB Ratings Summary
ETNB Quant Ranking